Kiromic BioPharma (KRBP) Welcomes Two New Directors to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Kiromic BioPharma Welcomes Two New Directors to its Board
July 24, 2023 3:00 PM EDTClinical and Regulatory Affairs Expert Pamela Misajon Brings Drug-Development Expertise
Finance and Technology Executive Michael Catlin to Chair the Audit Committee
HOUSTON--(BUSINESS WIRE)-- Kiromic BioPharma, Inc. (NASDAQ: KRBP) (Kiromic or the Company), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the appointments of Pamela Misajon and Michael Catlin to its Board of Directors. Their regulatory and finance experience enhances Kiromics governance and re-establishes the Companys... More
